Check for updates

OPEN ACCESS

EDITED BY Fabio Grizzi, Humanitas Research Hospital, Italy

REVIEWED BY Dmitry Aleksandrovich Zinovkin, Gomel State Medical University, Belarus Asiya Khan, Amity University, India

*CORRESPONDENCE Buzhen Tan Manbuzhen@sina.com

RECEIVED 23 September 2024 ACCEPTED 07 February 2025 PUBLISHED 25 February 2025

CITATION

Peng W, Hu H, Huang G, Wu X, Zhu Y, Yang T, Tao X and Tan B (2025) Compound cancer with small cell carcinoma and mucinous adenocarcinoma of the ovary: a case report and literature review. *Front. Oncol.* 15:1500088. doi: 10.3389/fonc.2025.1500088

COPYRIGHT

© 2025 Peng, Hu, Huang, Wu, Zhu, Yang, Tao and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Compound cancer with small cell carcinoma and mucinous adenocarcinoma of the ovary: a case report and literature review

Wan Peng¹, Hui Hu¹, Genhua Huang¹, Xiaoyun Wu¹, Yichen Zhu¹, Tian Yang¹, Xin Tao² and Buzhen Tan^{1*}

¹Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China, ²Department of Pathology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China

Primary small cell carcinoma of the ovary is an extremely rare and highly malignant ovarian malignancy. The tissue origin of this type of cancer is still unclear, and it is characterized by rapid progression and a discouraging prognosis. The clinical presentation of small cell carcinoma of the ovary lacks specificity, and there are currently no effective treatment options available. Therefore, it is crucial to improve the understanding and identification of this disease. In this paper, we present a case of composite small cell carcinoma of the ovary with mucinous adenocarcinoma and provide a comprehensive review of the relevant literature.

KEYWORDS

ovarian cancer, small cell carcinoma, mucinous adenocarcinoma, gynecologic tumor, case report

1 Introduction

Ovarian cancer is one of the three primary malignant neoplasms that affect the female reproductive system, with compound ovarian cancer constituting a rare presentation that accounts for fewer than 1% of all ovarian tumors (1). A mixture of small cell carcinoma and mucinous carcinoma of the ovary is even more rarely observed, and only seven cases of this unique type of compound carcinoma have been reported in the literature in both China and internationally (2–8). In the 2014 edition of the World Health Organization (WHO) Classification of Tumors of the Female Genital Organs, small cell carcinoma of the ovary (SCCO) is categorized as a miscellaneous ovarian tumor due to its unclear histologic origin. Based on clinical and pathologic characteristics, SCCO can be further divided into two subtypes: ovarian small cell carcinoma of the hypercalcemic type (SCCOHT) and ovarian small cell carcinoma of the Female Genital Organs then reclassified small cell carcinoma of the Female Genital Organs then reclassified small cell carcinoma of the pulmonary type (SCCOPT) (9). The 2020 edition of the WHO Classification of Tumors of the Female Genital Organs then reclassified small cell carcinoma of miscellaneous ovarian tumors into two categories: the hypercalcemic type and the large-cell variant. Furthermore, in this updated classification, SCCOPT

incorporated into the discussion of neuroendocrine tumors for the first time (10). We herein describe a rare case of compound ovarian cancer, i.e., small cell carcinoma with mucinous adenocarcinoma of the ovary. Considering its clinical significance, we believe that it merits further attention.

2 Case description

Our case involved a 24-year-old young woman with no previous history of pregnancy or marriage. Her menarche was at 12 years of age, and her menstrual cycle was regular, with no evidence of menorrhagia or dysmenorrhea. Her medical history included anxious depression for 3 years, and she was under treatment with oral trazodone hydrochloride. Other than this, she had no remarkable past medical history and did not reflect a family history of cancer. She was referred to our hospital on 20 July 2023 due to abdominal pain and distension for 1 week and the discovery of a pelvic mass. The abdomen was distended under full abdominal pressure with no rebound pain. On internal examination, a full-term pregnant uterine mass could be palpated in the pelvis, and there was tension, a clear demarcation, and tenderness.

The results of the tests conducted in the laboratory were as follows: a blood calcium of 2.22 mmol/L; serum cancer antigen 125 (CA125) of 334.10 U/ml; serum alpha-fetoprotein, 35.1 ng/ml; and human epididymal protein 4 (HE4), 84 pmol/L (normal ranges, 2.11–2.52 mmol/L, 0–35 U/ml, 0–8.1 ng/ml, and 29.25–68.50 pmol/L, respectively). Routine blood tests showed the following: white blood cell count, 11.03×10^9 /L; red blood cell count, 3.67×10^{12} /L; hemoglobin, 105 g/L; platelet count, 346×10^9 /L; neutrophilic granulocyte percentage, 78.7%; lymphocyte percentage, 13.5% (normal ranges, $3.5-9.5 \times 10^9$ /L, $3.8-5.1 \times 10^{12}$ /L, 110-150 g/L, $125-350 \times 10^9$ /L, 40%–75%, and 20%–50%, respectively).

Transvaginal color ultrasound scan showed a cystic, predominantly mixed echogenic mass with multiple septations, and a small blood flow signal was detected on the septations in the lower abdomen that measured approximately $40 \text{ cm} \times 45 \text{ cm} \times 15 \text{ cm}$ (Figures 1A, B).

Whole-abdomen enhanced computed tomography showed large cystic solid occupations in the abdominopelvic cavity (size, approximately 135 mm \times 189 mm), and cystic solid tumor of left adnexal origin was considered. We also noted thickening of the omentum and the peritoneum and accumulation of fluid in the abdominopelvic cavity. In addition, we observed bilateral pleural effusion, a small amount of pericardial effusion, and several lymph nodes in the right cardio phrenic angle (Figures 1C–F).

Pelvic magnetic resonance (MR) imaging revealed a large, cystic solid mass in the abdominopelvic cavity with long T1 and T2 signals and multiple linear segregations, with the solid portion of the lesion manifesting slightly shorter T1 signals and slightly longer T2 signals. The solid portion of the lesion and the segregation showed obviously uneven enhancement that was most closely juxtaposed to the left adnexa. Our impression was of a large, cystic-solid occupancy in the abdominopelvic cavity, and we considered it to be a cystic-solid tumor of left adnexal origin that suggested malignancy when assessed using tumor indicators. We also noted thickening of the omentum and peritoneum and abdominopelvic effusion (Figures 2A–D).

3 Intraoperative exploration

The patient was suspected of having an ovarian malignancy, so she underwent an exploratory laparotomy on July 24, 2023 under general anesthesia. A large, cystic solid mass was observed in the pelvis, measuring approximately $40 \text{ cm} \times 45 \text{ cm} \times 30 \text{ cm}$, which was partially cystic and partially solid, with dense adhesions to the mesentery and greater omentum. After the separation of the adhesions, the mass appeared to have originated from the left ovary. The right ovary was inflammatory and congested, and there was no obvious abnormality in either fallopian tube. The mass and the left adnexa were completely resected and the pelvic and abdominal cavities were explored. We found no lesions in the uterus, the right adnexa, the left fallopian tube, the pelvic wall, the abdominal wall, the greater omentum, the intestinal surface, the liver, the spleen, or the stomach. Finally, we measured the weight of this tumor to be about 1.8326 kilograms (after aspiration of 1300 mL of intracapsular fluid) (Figures 3A, B). Rapid intraoperative pathology indicated a malignancy in the left ovary. The ovarian tumor was ruptured during surgery, and we thus described it as stage IC1. The patient's family stated that the young woman was unmarried and childless and that they wished to preserve her fertility and not to expand the scope of surgery. Therefore, only a left salpingo-oophorectomy was performed.

4 Postoperative pathology

Macroscopic findings of the left ovary and tumor specimen showed a nodular mass that measured 23.5 cm \times 17.5 cm \times 8 cm, was cystic solid in section, contained bloody fluid, showed solid areas in the form of nodules, and was 1.5-5.5 cm in diameter, grayish-yellowish-grayish-red, and soft. The fibrous cystic wall was lined with monolayer high columnar epithelium microscopically, and cellular heterogeneity was observed in some areas. Two tumor cell types were noted in the solid area, with cells observed in a nested sheet or pseudopapillary arrangement in the majority of the area; some cells manifested fine nuclear staining, and some cells possessed large nuclei with eosinophilic nucleoli. The cells were arranged in an adenoidal pattern in a small portion of the area, and intracellular mucus, hemorrhage, and necrosis were seen. There were no neoplastic changes in the left fallopian tube. Immunohistochemical staining showed small cell carcinoma cells that were cytokeratin (+), chromogranin A (+), synaptophysin (+), CA199 (+), Pax8 weakly (+), P53 wild-type expression, and Ki-67 about 40% (+). CEA, CK7, Vim, SALL4, OCT4, AFP, CD117, CD30, S100, uroplakin, WT-1, P16, inhibin, calretinin, and EMA were (-). The adenocarcinoma cells were cytokeratin (+), chromogranin A partially (+), synaptophysin partially (+), CEA (+), CK7 partially (+), EMA (+), and Pax8 (+). The P53 showed wild-type expression, with CD30 scattered weakly (+), and the Ki-




FIGURE 1

(A, B) Transvaginal color ultrasound scan: The left ovary showed unclear and there was a predominantly cystic mixed echogenic mass in the lower abdomen (size about 40 cm \times 45 cm \times 15 cm). (C-F) Whole-abdomen enhanced computed tomography images: There was a large cystic solid mass (red arrow) in the abdominopelvic cavity that was in close proximity to the left adnexa (white arrow).

67 was at about 40% (+). CA199, Vim, SALL4, OCT4, AFP, CD117, S100, uroplakin, WT-1, P16, inhibin, and calretinin were (-). Ascites cytology exhibited no malignant tumor cells, and no abnormal ploidy cells were seen. Upon histopathologic examination, we determined that the excised specimens contained both small cell carcinomas and mucinous adenocarcinoma (Figures 4A–H).

5 Follow-up after surgery

The patient refused to continue treatment such as adjuvant chemotherapy or radiotherapy after the operation and went home to receive local traditional Chinese medicine (TCM) treatment. However, only 2 months after the operation, she developed abdominal distension and pain as well as chest tightness and dyspnea. Later, she underwent a Computed tomography (CT) scan at the local hospital because of increased abdominal distension. The results showed that she had right-sided pneumonia with a large amount of fluid in the right thoracic cavity and a small amount of fluid in the left thoracic cavity. And she had multiple round-like soft tissue-like masses with peritoneal fluid and omental thickening in the right abdominal cavity. After a week, her symptoms were still not relieved, so she was transferred to our hospital on October 11, 2023 for treatment. We supplemented her with a pelvic magnetic resonance (MR) examination, which showed a large mixed cystic-solid mass in her pelvis with a cross-section of approximately $122 \times 95 \times 116$ mm, and the structural tissues around the mass were compressed and displaced as a result.




FIGURE 2

Pelvic magnetic resonance images. (A–D) Preoperative pelvic magnetic resonance images: Abdominopelvic cavity shows a large, cystic solid mass. Solid and septal portions of the lesion show marked inhomogeneity that was in close proximity to the left adnexa (red arrows). (E, F) Three month postoperative pelvic magnetic resonance images: There was a large cystic-solid mass (cross-sectional size of about 122 × 95 × 116 mm) in the pelvis (red arrows), and the adjacent structural tissues were displaced by its compression.

The cystic wall and solid portion showed marked heterogeneous enhancement, and the subcutaneous soft tissues of the abdominopelvic wall appeared swollen. She had fluid accumulation in the abdominal and pelvic cavities, thickened and rough peritoneum, and localized nodular changes in the peritoneum (Figures 2E, F). Therefore, we considered that she might have tumor recurrence as well as peritoneal metastasis. After we treated her with symptomatic supportive therapy such as oxygen, anti-infection, drainage by thoracentesis and abdominal puncture, the patient's symptoms were slightly relieved. Our multiple disciplinary team (MDT) also discussed her condition and subsequent treatment modalities, and originally planned to perform surgery after her condition improved, but the patient and family ultimately gave up the treatment. She eventually died on June 9, 2024 due to the deterioration of her condition. From the date the disease was first detected, she survived for only about 11 months.



6 Discussion

It is extremely rare to have both mucinous adenocarcinoma and small cell carcinoma of the ovary. To our knowledge, including the present Case Report, this compound ovarian cancer has only been reported eight times thus far (Supplementary Table 1) (2–8).

Previous studies have indicated that SCCOHT exhibits a higher prevalence among young women, typically manifesting at an average age of 24 years. In contrast, SCCOPT is predominantly observed in middle-aged and older women, with an average age at onset of 54 years (11, 12). The clinical manifestations of SCCO lack specificity. SCCO is commonly characterized by symptoms such as abdominal pain and distension, pelvic mass, and pressure on adjacent organs. In addition, acute abdominal symptoms can arise due to torsion or rupture of the tumor, as well as irregular vaginal bleeding (11, 12). Approximately two-thirds of patients with SCCOHT exhibited elevated blood calcium levels, with a minority of patients experiencing symptoms related to hypercalcemia including nausea, vomiting, irritable thirst, and polyuria. These symptoms may be attributed to the paracrine action of the tumor cells that generates parathyroid hormone-related protein (PTHrp) (13). Conversely, SCCOPT does not parallel hypercalcemia, and its prognosis is inferior to that of SCCOHT. SCCOHT and SCCOPT generally exhibit a negligible variation in morphology, with unilateral ovarian involvement and a large tumor size. The tumors are principally solid but often accompanied by various levels of cystic degeneration, hemorrhage, and necrosis. Additionally, the majority of affected patients exhibit elevated serum CA125 levels (14). Our patient was a 24-year-old individual who exhibited symptoms of abdominal pain and distension. The localization of the tumor was identified within the left ovary, and the tumor measured approximately 40 cm in size. Morphologically, the tumor showed a cystic solid structure that was accompanied by evident hemorrhage and necrotic areas, and this




FIGURE 4

(A–H) Histopathological and immunohistochemical images: (A, B) Small cell carcinomas: tumor cells are organized in clusters or pseudopapillae with well-stained nuclei (A: H&E, x100; B: H&E, x400); (C) Mucinous adenocarcinoma: mucus is seen within the cells, and the cells are arranged in an adenoidal pattern (H&E, x100); (D–H) immunohistochemical features of the tumor (EnVision, x100): Small-cell carcinoma was positive for CgA (D) and Syn (E), for Ki-67 expression at approximately 40% (F), and for cytokeratin (G); mucinous adenocarcinoma was positive for cytokeratin (H).

was consistent with the findings reported in the extant literature. Although the patient's pre-operative blood calcium level fell within the normal range, elevated serum levels of CA125, AFP, and HE4 were observed. It is important to note that while blood calcium levels reflect some diagnostic value in the identification of SCCOHT, its specificity remains limited. Therefore, definitive confirmation of the diagnosis relies upon subsequent pathologic examination and immunohistochemical analysis.

The hypercalcemic type Is one where the tumor cells are manifest as follicle-like lumens of varying sizes and irregular shapes, and the lumens contain eosinophilic gelatinous material. The tumor cells are primarily composed of rounded or ovoid clusters of small cells that can be arranged in sheets, islands, strips, or beams with little cytoplasm, and they exhibit small, dark-stained nuclei with active nuclear schizophrenic phenomena. SCCOHT and malignant rhabdomyoid tumors (MRTs) exhibit morphologic similarities (15). Both types of tumors exhibit large eosinophilic cells with ample cytoplasm, noticeable nucleoli, and vacuolated nuclei. SCCOPT resembles small cell neuroendocrine carcinoma of the lung and is characterized by small tumor cells that are arranged in sheets, tight nests, islands, or beams (12). The cells have a fine pretzel-like nuclear chromatin, sparse cytoplasm, and inconspicuous nucleoli, and they frequently exhibit nuclear schizophrenia. Follicle-like structures and large cellular components are rarely seen in the tumor tissue. Immunohistochmical staining of SCCOHT tumor tissues frequently demonstrates the expression of EMA, cytokeratin, and calretinin, while typically lacking α -inhibin, S100, desmin, and thyroid transcription factor-1. In contrast, immunohistochemical staining of SCCOPT tumor tissues generally shows positive staining for chromogranin A, CD56, synaptophysin, and neuralspecific enolase. SCCOPT also shows expression of EMA and cytokeratin, but α -inhibin is rarely detectable. Recent research has shown that over 90% of SCCOHT cases are associated with mutations in the SMARCA4 geneand that these mutations can result in the loss of BRG1 protein expression. The absence of expression of both SMARCA4 and SMARCA2 has also been identified as a highly accurate and specific indicator for the diagnosis of SCCOHT (16). In our case, chromogranin A and synaptophysin were positive, and cytokeratin and P53 were expressed; while EMA, calretinin, inhibin, and S100 were not expressed, suggesting a diagnosis of SCCOPT. Because our immunohistochemical results proved that the patient had ovarian small cell carcinoma complicated with mucinous adenocarcinoma, and CD56, BRG1, INI-1, TFF-1, and SOX-2 were only suggested to be expressed in some literatures, we did not test the immunohistochemical results for CD56, BRG1, INI-1, TFF-1, and SOX-2. Due to the lack of availability of further genetic testing and an overlap in histologic presentation and immunohistochmical localization between SCCOHT and SCCOPT we were not confident in distinguishing between them. In terms of tissue origin, SCCO is similar to ovarian epithelial tumors, ovarian gonadal mesenchymal tumors, and germ cell tumors. Furthermore, it is important to differentiate SCCO from metastases of neuroendocrine carcinomas originating in the lungs or other organs (12, 13).

SCCO has an extremely poor prognosis, with most patients dying or relapsing within a year or two. The prognosis of SCCO is worse than that of ovarian mucinous adenocarcinoma, and thus, the prognosis of this composite cancer depends more on SCCO. Out of the eight reported patients, five succumbed within a period of 10 months, with the majority exhibiting signs of metastasis, particularly in the peritoneum and liver (2-4, 7, 8). Our patient also experienced tumor recurrence and metastasis within 3 months after surgery and died less than 11 months later. It is highly advantageous to have an early FIGO stage, an age of at least 30 years, a normal preoperative calcium level, a tumor diameter of over 10 cm, and few large cellular components when it comes to SCCOHT (11). There is presently no standard treatment for SCCO, with surgery and chemotherapy being the primary treatments. The surgical treatments include total hysterectomy, salpingo-oophorectomy, appendectomy, and full pelvic and para-aortic lymphadenectomy. Furthermore, tumor cytoreduction surgery is feasible for patients with intermediate-toadvanced disease (16, 17). Due to the high malignancy of the disease and poor prognosis, it is controversial as to whether young women can preserve their fertility if they contract it. While postoperative adjuvant chemotherapy is crucial to prolonging patient survival, there is currently a paucity of standardized chemotherapeutic regimens. Commonly used treatments include combinations of platinum and etoposide (e.g., BEP, VPCBAE, and PAVEP) and combinations of platinum and paclitaxel. Multimodal radiotherapy can be administered after chemotherapy, but its effectiveness is unclear. Some guidelines recommend the use of high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) to prolong survival in patients who achieved a complete response (CR) by cytoreduction surgery or 4-6 cycles of chemotherapy (18). In addition, epigenetic therapies, kinase inhibitors, and immunosuppressive drugs are also effective against SCCO (13). Although postoperative adjuvant therapy has a prognostic impact, our patient ultimately opted out of these treatment modalities.

7 Conclusions

In conclusion, SCCO combined with mucinous ovarian cancer is extremely rare, and due to the lack of specificity in its clinical and pathologic manifestations, it is easily misdiagnosed as another type of ovarian tumor. Current treatment options for this disease remain limited, as conventional treatments such as surgical resection and chemotherapy are not always effective for this rare tumor type. Further research is therefore needed to uncover more precise and effective treatments. It is crucial for clinicians and pathologists to improve our understanding and identification of this disease. We posit that early diagnosis and accurate pathologic analysis will facilitate the development of individualized treatment plans and improve patient survival and the quality of life of patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Ethics Committee in the Second Affiliated Hospital of Nanchang University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

WP: Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing, Formal analysis, Visualization. HH: Conceptualization, Data curation, Writing – original draft, Validation. GH: Data curation, Methodology, Supervision, Writing – original draft. XW: Data curation, Supervision, Writing – review & editing, Resources. YZ: Investigation, Resources, Writing – review & editing. TY: Investigation, Resources, Writing – review & editing. XT: Resources, Writing – review & editing. BT: Conceptualization,

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* (2021) 71:209–49. doi: 10.3322/caac.21660

2. Jones K, Diaz JA, Donner LR. Neuroendocrine carcinoma arising in an ovarian mucinous cystadenoma. *Int J Gynecol Pathol: Off J Int Soc Gynecol Pathol.* (1996) 15:167–70. doi: 10.1097/00004347-199604000-00012

3. Collins RJ, Cheung A, Ngan HYS, Wong LC, Chan SYW, Ma HK. Primary mixed neuroendocrine and mucinous carcinoma of the ovary. *Arch Gynecol Obstet.* (1991) 248:139–43. doi: 10.1007/BF02390091

4. Khurana KK, Tornos C, Silva EG. Ovarian neuroendocrine carcinoma associated with a mucinous neoplasm. Arch Pathol Lab Med. (1994) 118:1032–4.

5. Grandjean M, Legrand L, Waterkeyn M, Baurain J-F, Jadoul P, Donnez J, et al. Small cell carcinoma of pulmonary type inside a microinvasive mucinous cystadenocarcinoma of the ovary: a case report. *Int J Gynecol Pathol: Off J Int Soc Gynecol Pathol.* (2007) 26:426–31. doi: 10.1097/pgp.0b013e318039373a

6. Qu LM, Zhong YP, Guo L, Ni JS. mucinous cystadenocarcinoma of ovary associated with neuroendocrine carcinoma (primary ovarian pulmonary-type small cell carcinoma): report of a case. *Zhonghua Bing Li Xue Za Zhi = Chin J Pathol.* (2018) 47:380–2. doi: 10.3760/cma.j.issn.0529-5807.2018.05.015

7. Wei J, Wang Y, Li P, Fan L, Li M, Wang Z. Small-cell carcinoma-associated ovarian mucinous carcinoma: a case report and literature review. *Pathol Res Pract.* (2019) 215:426–31. doi: 10.1097/pgp.0b013e318039373a

Writing – original draft, Funding acquisition, Project administration, Supervision, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1500088/ full#supplementary-material

8. Mannan SA, Azhar M, Iftikhar J, Chaudhry SK, Hameed M. A rare presentation of dual ovarian pathologies: small cell carcinoma of the ovary and mucinous ovarian cancer. *Cureus*. (2021) 13(11):e19468. doi: 10.7759/cureus.19468

9. Lu Z, Chen J. introduction of WHO classification of tumours of female reproductive organs, fourth edition. *Zhonghua Bing Li Xue Za Zhi = Chin J Pathol.* (2014) 43:649–50. doi: 10.3760/cma.j.issn.0529-5807.2014.10.001

10. McCluggage WG, Singh N, Gilks CB. Key changes to the world health organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). *Histopathology*. (2022) 80:762–78. doi: 10.1111/his.14609

11. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. *Am J Surg Pathol.* (1994) 18:1102–16. doi: 10.1097/00000478-199411000-00004

12. Chen X, Liu H-L, Wang J-S, Zhao F-H. Primary ovarian small cell carcinoma of pulmonary type: analysis of 6 cases and review of 31 cases in the literatures. *Chin Med Sci J* = *Chung-Kuo Hsueh K'o Hsueh Tsa Chih.* (2023) 38:130–7. doi: 10.24920/004183

13. Simões MFE, Da Costa AABA, Silva TN, Fernandes L, Bovolim G, Torrezan GT, et al. Case report of small cell carcinoma of the ovary, hypercalcemic type (ovarian rhabdoid tumor) with SMARCB1 mutation: a literature review of a rare and aggressive condition. *Curr Oncol.* (2022) 29:411–22. doi: 10.3390/curroncol29020037

14. Wens FSPL, Hulsker CCC, Fiocco M, Zsiros J, Smetsers SE, de Krijger RR, et al. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): patient characteristics, treatment, and outcome-a systematic review. *Cancers*. (2023) 15:3794. doi: 10.3390/cancers15153794

15. Coşkun Ç, Kurucu N, Usubutun A, Soyer T, Ozcan HN, Çelik Ertaş NB, et al. Small cell carcinoma of ovary, hypercalcemic type: a rare case report. *J Pediatr Adol Gynec.* (2023) 36:112–5. doi: 10.1016/j.jpag.2022.10.004

16. Tischkowitz M, Huang S, Banerjee S, Hague J, Hendricks WPD, Huntsman DG, et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. *Clin Cancer Res.* (2020) 26:3908–17. doi: 10.1158/1078-0432.CCR-19-3797

17. Hu D, Ma D, Zhang ZJ, Zhang Y, Huang K, Li X. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: a retrospective observational cohort study. *Front Endocrino*. (2023) 14:1103429. doi: 10.3389/fendo.2023.1103429

18. Sessa C, Schneider DT, Planchamp F, Baust K, Braicu EI, Concin N, et al. ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. *Lancet Oncol.* (2020) 21:e360–8. doi: 10.1016/S1470-2045(20)30091-7